ImmunityBio Files Q1 2025 10-Q
Ticker: IBRX · Form: 10-Q · Filed: May 12, 2025 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotechnology, financials
TL;DR
ImmunityBio's Q1 2025 10-Q is in. Check financials.
AI Summary
ImmunityBio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as NantKwest, Inc., is involved in the biological products sector. The filing details its financial position and business operations for the first quarter of 2025.
Why It Matters
This filing provides investors with an update on ImmunityBio's financial health and operational status, crucial for understanding the company's trajectory in the biotechnology sector.
Risk Assessment
Risk Level: medium — Biotechnology companies often face high risks due to research and development costs, regulatory hurdles, and market competition.
Key Players & Entities
- ImmunityBio, Inc. (company) — Filer of the 10-Q
- NantKwest, Inc. (company) — Former name of ImmunityBio, Inc.
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date
- 3530 JOHN HOPKINS COURT, SAN DIEGO, CA 92121 (location) — Company's business and mailing address
FAQ
What is the primary business of ImmunityBio, Inc.?
ImmunityBio, Inc. is in the Biological Products sector, specifically excluding diagnostic substances, as indicated by its SIC code 2836.
When was the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing was March 31, 2025.
What was ImmunityBio, Inc. formerly known as?
ImmunityBio, Inc. was formerly known as NantKwest, Inc., Conkwest, Inc., and ZelleRx Corp.
What is the company's business address?
The company's business address is 3530 John Hopkins Court, San Diego, CA 92121.
What is the SEC file number for ImmunityBio, Inc.?
The SEC file number for ImmunityBio, Inc. is 001-37507.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding ImmunityBio, Inc. (IBRX).